VRDN Q3 2025 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M+81958.1% YoY

Gross Profit

$71M100.0% margin

Operating Income

-$40M-56.7% margin

Net Income

-$35M-49.0% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+93993.3%

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$85M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$577M

Total Liabilities

$74M

Stockholders' Equity

$503M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$86,000	+81958.1%
Gross Profit	$71M	$86,000	+81958.1%
Operating Income	-$40M	-$83M	+52.1%
Net Income	-$35M	-$77M	+54.9%

Revenue Segments

License

$70M99%

Collaboration

$570,0001%